EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Perspectives: what we are learning from factor XI/factor XIa inhibitor trials

Melissa F Glasner, Jeffrey I Weitz, Rasha Al-Lamee, María Cecilia Bahit, Jonathan M Coutinho, S Claiborne Johnston, David Gailani, Carolyn S P Lam, Tzu-Fei Wang, Wolfgang C Winkelmayer

Research and Practice in Thrombosis and Haemostasis · 2026-09 · 10 · 106936

DOI: 10.1016/j.rpth.2026.106936 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026-09. Verfasst von Melissa F Glasner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, The France Foundation, Old Lyme, Connecticut, USA. Hauptthemen laut MEDLINE: Factor XI, Factor XIa, Thrombosis, Fibrinolytic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer US, Anthos Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor XIFactor XIaThrombosisFibrinolytic AgentsAnticoagulantsBlood CoagulationHumansClinical Trials as Topic

Stichwörter der Autor:innen

anticoagulantsblood coagulationfactor XIhemostasisthrombosis

Substanzen

Factor XIFactor XIaFibrinolytic AgentsAnticoagulants

Autor:innen und Institutionen

  • Department of Medical Education, The France Foundation, Old Lyme, Connecticut, USA.
  • Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • National Heart and Lung Institute, Imperial College Healthcare NHS, London, UK.
  • Department INECO Neurociencias, World Stroke Organization Heart and Brain Task Force, Rosario, Argentina.
  • Department of Neurology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Department of Neurology, University of California, San Francisco, California, USA.

Förderung

  • Bayer US
  • Anthos Therapeutics

Zitieren

APA

Glasner, M. F., Weitz, J. I., Al-Lamee, R., Bahit, M. C., Coutinho, J. M., Johnston, S. C., Gailani, D., Lam, C. S. P., Wang, T. F., & Winkelmayer, W. C. (2026). Perspectives: what we are learning from factor XI/factor XIa inhibitor trials. Research and Practice in Thrombosis and Haemostasis, 10, 106936. https://doi.org/10.1016/j.rpth.2026.106936

Vancouver

Glasner MF, Weitz JI, Al-Lamee R, Bahit MC, Coutinho JM, Johnston SC, et al. Perspectives: what we are learning from factor XI/factor XIa inhibitor trials. Research and Practice in Thrombosis and Haemostasis. 2026;10:106936. doi:10.1016/j.rpth.2026.106936

BibTeX
@article{Glasner2026,
  author = {Glasner, Melissa F and Weitz, Jeffrey I and Al-Lamee, Rasha and Bahit, María Cecilia and Coutinho, Jonathan M and Johnston, S Claiborne and Gailani, David and Lam, Carolyn S P and Wang, Tzu-Fei and Winkelmayer, Wolfgang C},
  title = {Perspectives: what we are learning from factor XI/factor XIa inhibitor trials},
  journal = {Research and Practice in Thrombosis and Haemostasis},
  year = {2026},
  volume = {10},
  pages = {106936},
  doi = {10.1016/j.rpth.2026.106936}
}
Kostenlos starten →